<DOC>
	<DOCNO>NCT00871559</DOCNO>
	<brief_summary>The purpose study assess safety tolerability REGN421 ( SAR153192 ) patient advance solid malignancy .</brief_summary>
	<brief_title>A Multiple-Ascending-Dose Study Safety Tolerability REGN421 ( SAR153192 ) Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Male female 18 year age old 2 . Histologically diagnosis advance solid malignancy , standard therapeutic option prove benefit . 3 . Patients measurable nonmeasurable disease 4 . At least 6 week must elapse since last dose bevacizumab ( AvastinTM ) 5 . At least 4 week must elapse since last major surgery 6 . For woman childbearing potential , negative urine pregnancy test screen visit 7 . Willingness use adequate contraception full course study . Systemic hormonal contraceptive agent exclude 8 . Willing , commit , able return ALL clinic visit complete studyrelated procedure . 9 . Able read , understand willing sign inform consent form 1 . Medical history myocardial infarction cardiomyopathy 2 . Unstable angina 3 . NYHA class II IV congestive heart failure 4 . Patients treatment 2 antihypertensive medication 5 . History bleed peptic ulcer disease , erosive gastritis , intestinal perforation , clinically significant GI hemorrhage within 6 month study drug administration 6 . Diabetic retinopathy 7 . Patients require anticoagulation 8 . Hypersensitivity doxycycline relate compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>